EGFR (V769_D770insGE)

EGFR · Variant type: indel · HGVS: p.V769_D770insGE

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Mobocertinib	99.3%	0.7%	97.22
2	Lazertinib	98.1%	1.9%	97.47
3	Pralsetinib	97.9%	2.1%	93.43
4	Canertinib	97.7%	2.4%	96.49
5	Neratinib	95.7%	4.3%	93.18
6	Erlotinib	94.2%	5.8%	99.75
7	Vandetanib	93.9%	6.1%	95.74
8	Alpelisib	68.9%	31.1%	97.22
9	Pacritinib	61.2%	38.8%	88.64
10	Zanubrutinib	25.4%	74.6%	98.24
11	Pemigatinib	22.6%	77.4%	98.23
12	Defactinib	18.1%	81.9%	92.68
13	Pirtobrutinib	13.9%	86.1%	99.49
14	Capmatinib	11.6%	88.4%	99.75
15	Pexidartinib	10.8%	89.2%	99.49
16	Capivasertib	9.6%	90.4%	96.48
17	Gilteritinib	6.3%	93.8%	88.97
18	Upadacitinib	3.9%	96.1%	97.98
19	Tenalisib	2.9%	97.1%	97.98
20	Asciminib	2.9%	97.1%	100.00
21	Quizartinib	2.6%	97.4%	99.50
22	Umbralisib	2.6%	97.4%	98.74
23	Idelalisib	0.0%	100.0%	100.00
24	Futibatinib	0.0%	100.0%	98.48
25	Erdafitinib	0.0%	100.0%	95.71

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Mobocertinib	99.3%	100.0%	-0.7%
Lazertinib	98.1%	100.0%	-1.9%
Pralsetinib	97.9%	99.1%	-1.2%
Canertinib	97.7%	98.4%	-0.8%
Neratinib	95.7%	100.0%	-4.3%
Erlotinib	94.2%	99.4%	-5.2%
Vandetanib	93.9%	99.3%	-5.4%
Alpelisib	68.9%	—	—
Pacritinib	61.2%	—	—
Zanubrutinib	25.4%	88.2%	-62.8%
Pemigatinib	22.6%	—	—
Defactinib	18.1%	94.6%	-76.5%
Pirtobrutinib	13.9%	—	—
Capmatinib	11.6%	—	—
Pexidartinib	10.8%	—	—
Capivasertib	9.6%	—	—
Gilteritinib	6.3%	91.0%	-84.8%
Upadacitinib	3.9%	—	—
Tenalisib	2.9%	—	—
Asciminib	2.9%	—	—
Quizartinib	2.6%	—	—
Umbralisib	2.6%	—	—
Idelalisib	0.0%	—	—
Futibatinib	0.0%	—	—
Erdafitinib	0.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.5ms